Emergency and ICU pharmacists would be most likely to see pneumonic plague. An expert reviews first-line agents, alternatives, and postexposure prophylaxis.
|Videos|September 17, 2015
How Community Pharmacies Have Been Impacted By New Trends
Doug Long, vice president of industry relations at IMS Health, talks about how community pharmacies have been impacted by new trends in the industry.
Advertisement
Doug Long, vice president of industry relations at IMS Health, talks about how community pharmacies have been impacted by new trends in the industry.
This video was recorded at the 2015 NACDS Total Store Expo.
Advertisement
Related to this article
A former residency program director unpacks why this debate keeps resurfacing, and why some reasons people give for skipping residency may not hold up the way they think they do.
Eric Lawitz, MD, explains how pharmacists can raise liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.
Pharmacogenomic-guided prescribing uses genetic data to protect patients from dangerous toxicities and get them the right drug at the right dose from the start.
As accessible health care providers, pharmacists can raise awareness about the proper use of OTC blood glucose meters and continuous glucose monitoring devices.
The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.
Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague, and which antibiotics the CDC recommends.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
2
Pneumonic Plague: What Pharmacists Need to Know About Treatment
3
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
4
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
5